Liferol

Formoterol Fumarate, the active ingredient in Liferol, is a long‑acting β2‑adrenergic agonist (LABA) presented as an inhalation formulation for inhalation use. It treats asthma and chronic obstructive pulmonary disease (COPD) in adult patients. GNH USA supplies Liferol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Formoterol Fumarate is a bronchodilator that acts on the airway smooth‑muscle pathway to improve airflow in chronic respiratory diseases.

Asthma: improves bronchodilation and symptom control for maintenance therapy. COPD: enhances lung function and reduces the frequency of exacerbations. Exercise‑induced bronchoconstriction (as part of combination therapy): helps prevent bronchospasm during physical activity.

Formoterol Fumarate may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Tremor: mild shaking of hands or limbs. - Headache: transient cranial discomfort. - Throat irritation: dryness or soreness after inhalation. - Cough: occasional irritation of the airway. - Palpitations: awareness of heartbeat. - Muscle cramps: occasional limb discomfort.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Tachycardia: rapid heart rate requiring medical attention. - Hypokalemia: low blood potassium levels. - Angina: chest pain indicative of cardiac strain. - Arrhythmias: irregular heart rhythms. - Hypersensitivity reactions: rash, swelling, or anaphylaxis.

Formoterol Fumarate requires careful patient assessment and monitoring to minimise risks.

Assess cardiovascular status: patients with arrhythmias or ischemic heart disease should be monitored closely. Avoid abrupt discontinuation: sudden stopping may worsen asthma control. Use only as prescribed: overuse can increase the likelihood of adverse cardiac events. Do not combine with monoamine oxidase inhibitors: may precipitate severe hypertension. Pregnancy and lactation: safety not established; use only if the benefit outweighs potential risk. Store at ambient temperature: keep in the original container, protect from moisture and heat.

Formoterol Fumarate can interact with several drug classes, requiring attention to avoid reduced efficacy or heightened toxicity.

Major Interactions (Avoid): - Beta‑blockers: may diminish bronchodilator effect and precipitate bronchospasm. - Monoamine oxidase inhibitors: risk of hypertensive crisis. - Diuretics: can exacerbate hypokalemia.

Moderate Interactions (Monitor Closely):\n- Other long‑acting β2‑agonists: additive cardiovascular stimulation may increase tachycardia risk. - Anticholinergic bronchodilators: combined use may cause excessive bronchodilation and tachyarrhythmias.